On February 15, 2022 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", the company) reported that the first bispecific antibody-receptor recombinant protein (project number: IMM2902) targeting human CD47 x HER2 has completed the first patient enrollment and dosing, and administration process was smooth and successful (Press release, ImmuneOnco Biopharma, FEB 15, 2022, View Source [SID1234655630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMM2902, a CD47xHER2 bispecific fusion protein designed for solid tumors, is at the forefront of global research. The project has previously been approved by the National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) for clinical trials on June 29, 2021 and August 21, 2021. It is the third new drug project in the clinical research stage of the company based on targeting CD47/SIRPa. The completion of the first subject enrollment and dosing in the IMM2902 project is another major milestone for the company.

Dr. Wenzhi Tian, Founder and CEO of the company, is very confident in the clinical trial research of IMM2902.

"We are very pleased that our IMM2902 project has completed the first patient in. IMM2902 is a bispecific molecule developed on our mAb-Trap technique platform for CD47 and HER2. The molecule preferentially binds to tumor cells through the high affinity to HER2 and CD47, at the same time, it doesn’t bind to human red blood cells and other off-target cells, so as to avoid the "Antigen sink" effect, thereby greatly enhance the synergistic effect based on both targets against tumors. IMM2902 will have great potential in clinical development and commercial value."

On February 15, 2022 Perrigo Company plc (NYSE; TASE: PRGO) reported that it will release its fourth quarter and fiscal year 2021 financial results on Tuesday, March 1, 2022 (Press release, Perrigo Company, FEB 15, 2022, View Source,-2022 [SID1234608131]). The Company will also host a conference call beginning at 8:30 A.M. (EST).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at View Source or by phone at 888-317-6003, International 412-317-6061, and reference ID # 3221228. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Tuesday, March 1, until midnight Tuesday, March 8, 2022. To listen to the replay, dial 877-344-7529, International 412-317-0088, and use access code 1209247.

On February 15, 2022 Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, reported that management will participate at the following upcoming investor conferences (Press release, Arcus Biosciences, FEB 15, 2022, View Source [SID1234608149]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Leerink 11th Annual Global Healthcare Conference
Date & Time: Wednesday, February 16th, 2022 at 1:20 p.m. PT
Format: Fireside Chat

Barclay’s Global Healthcare Conference
Date & Time: Thursday, March 17th, 2022 at 1:35 p.m. ET
Format: Fireside Chat

Live audio webcasts will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcasts will be available for at least two weeks following the live events.

On February 15, 2022 Incyte (Nasdaq:INCY) reported that it will present at the virtual Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET (Press release, Incyte, FEB 15, 2022, View Source [SID1234608113]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

On February 15, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, reported a licensing and collaboration agreement (Press release, Intellia Therapeutics, FEB 15, 2022, View Source [SID1234608132]). NK cells are specialized, naturally occurring immune cells that play a critical role in immune activation against abnormal cells, including cancer cells. NK cells have gained significant attention in the field of cancer immunotherapy and various approaches are being explored to effectively develop and engineer NK cell-based cancer immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement grants ONK a non-exclusive license to Intellia’s proprietary ex vivo CRISPR/Cas9-based genome editing platform and its lipid nanoparticle (LNP)-based delivery technologies to develop up to five allogeneic NK cell therapies. ONK will receive exclusive rights to certain Intellia guide RNAs (gRNAs) resulting from the collaboration for use in engineering those NK cell products. ONK will be responsible for preclinical and clinical development for the engineered NK cell therapies covered under the agreement. Intellia will be eligible to receive up to $184 million per product in development and commercial milestone payments, as well as up to mid-single digit royalties on potential future sales. In addition, the agreement grants Intellia options to co-develop and co-commercialize up to two products worldwide with rights to lead commercialization in the U.S. ONK retains lead commercialization rights ex-U.S. This co-development and co-commercialization option excludes ONK’s lead product ONKT-102, which is being developed for the treatment of patients with relapsed / refractory multiple myeloma, for which ONK retains sole rights. If Intellia chooses to exercise the co-development and co-commercialization option on an investigational product, in lieu of the potential royalties and milestones, Intellia will share 50 percent of any future profit and loss generated by the product.

"We look forward to working with ONK in the development of allogeneic NK cell therapies for patients with cancer. This collaboration, which combines Intellia’s industry-leading CRISPR technology platform and ONK’s expertise in NK cell technology, offers yet another powerful example of how we’re leveraging our strategic collaborations to address life-threatening diseases for patients in need," said Intellia President and Chief Executive Officer John Leonard, M.D.

"We believe combining Intellia’s ex vivo genome editing and LNP delivery platforms with our suite of proprietary NK cell gene edits has the potential to create optimally engineered NK cells with enhanced cytotoxicity, persistence and an improved metabolic profile that hold tremendous promise to advance the treatment of both hematologic malignancies and solid tumors. We are excited to partner with Intellia and are looking forward to a collaboration that allows us to continue to deliver against our strategy, as we evolve into a clinical-stage company," said ONK Therapeutics Chief Executive Officer Chris Nowers.